证券日报网讯11月13日晚间，新诺威（300765）发布关于发行股份购买资产并募集配套资金暨关联交易 之部分限售股份解除限售上市流通的提示性公告称，公司本次解除限售股东数量共计1名，解除限售股 份数量为157，520，510股，占公司总股本的11.2147%。本次限售股份可上市流通日期为2025年11月17 日(星期一)。 ...

格隆汇11月13日｜新诺威公告称，本次解除限售股东为恩必普药业，数量1名，解除限售股份1.58亿 股，占公司总股本的11.2147%，可上市流通日为2025年11月17日。业绩承诺方面，2022 - 2024年石药圣 雪已完成业绩承诺，无需进行业绩补偿；截至2024年底，其100%股权未发生减值，无需减值补偿。独 立财务顾问认为，本次限售股份解除限售和上市流通符合规定，相关股东无违反承诺情况。 ...

新诺威公告称，本次解除限售股东为恩必普药业，数量1名，解除限售股份1.58亿股，占公司总股本的 11.2147%，可上市流通日为2025年11月17日。业绩承诺方面，2022 - 2024年石药圣雪已完成业绩承诺， 无需进行业绩补偿；截至2024年底，其100%股权未发生减值，无需减值补偿。独立财务顾问认为，本 次限售股份解除限售和上市流通符合规定，相关股东无违反承诺情况。 ...

证券代码：300765 证券简称：新诺威 公告编号：2025-087 石药创新制药股份有限公司 关于发行股份购买资产并募集配套资金暨关联交易之部分 限售股份解除限售上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： （二）上述股份发行完成后至本公告披露之日公司总股本变化情况 公司本次发行股份购买资产并募集配套资金暨关联交易之向特定对象发行 股份募集配套资金的新增股份 31,486,146 股于 2023 年 3 月 10 日在深圳证券交易 所创业板上市，本次发行后公司总股本增加至 650,412,308 股。 公司于 2023 年 4 月 27 日完成 2022 年年度权益分派，其中以资本公积金向 全体股东每 10 股转增 8 股，转增后公司总股本增加至 1,170,742,154 股。 公司于 2024 年 4 月 25 日完成 2023 年年度权益分派，其中以资本公积金向 全体股东每 10 股转增 2 股，转增后公司总股本增加至 1,404,592,944 股。 2、本次限售股份可上市流通日为 2025 年 11 月 17 日 ...

之 部分限售股份解除限售上市流通 国投证券股份有限公司 关于 石药创新制药股份有限公司 发行股份购买资产并募集配套资金 暨关联交易 的核查意见 独立财务顾问 二零二五年十一月 国投证券股份有限公司（以下简称"国投证券"、"独立财务顾问"）作为 石药创新制药股份有限公司（以下简称"石药创新"、"公司"）发行股份购买 资产并募集配套资金暨关联交易（以下简称"本次交易"）的独立财务顾问，根 据《上市公司重大资产重组管理办法》《上市公司并购重组财务顾问业务管理办 法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》等相关规定，对本次交易部分限 售股份解除限售情况进行了核查，具体核查情况如下： 一、本次解除限售的股份取得和股本变化情况 （一）本次解除限售的股份取得情况 2022 年 10 月 12 日，公司收到中国证券监督管理委员会（以下简称"中国 证监会"）于 2022 年 10 月 8 日出具的《关于同意石药集团新诺威制药股份有限 公司向石药集团恩必普药业有限公司发行股份购买资产并募集配套资金注册的 批复》（证监许可[2022]2365 号），中国证监 ...

Group 1 - The core viewpoint of the news is that XinNuoWei's stock price increased by 5.18%, reaching 33.27 CNY per share, with a trading volume of 260 million CNY and a turnover rate of 0.64%, resulting in a total market capitalization of 46.731 billion CNY [1] - XinNuoWei, established on April 5, 2006, and listed on March 22, 2019, is primarily engaged in the research, production, and sales of functional foods, with revenue composition being 88.93% from functional foods and raw materials, 8.91% from biopharmaceuticals, and 2.16% from other sources [1] Group 2 - From the perspective of major circulating shareholders, E Fund's Chuangye ETF (159915) reduced its holdings by 1.3253 million shares in the third quarter, now holding 7.868 million shares, which accounts for 0.63% of circulating shares, with an estimated floating profit of approximately 12.9035 million CNY [2] - E Fund's Chuangye ETF (159915) was established on September 20, 2011, with a current scale of 110.2 billion CNY, achieving a year-to-date return of 47.69% and a one-year return of 32.24%, ranking 574 out of 4216 and 858 out of 3951 in its category, respectively [2] Group 3 - The fund managers of E Fund's Chuangye ETF are Cheng Xi and Liu Shurong, with Cheng having a tenure of 9 years and 193 days and a total fund asset size of 250.121 billion CNY, achieving a best return of 131.04% and a worst return of -67.89% during his tenure [3] - Liu Shurong has a tenure of 8 years and 121 days, managing assets totaling 141.127 billion CNY, with a best return of 194.12% and a worst return of -48.01% during his tenure [3]

Core Viewpoint - The announcement indicates that the company's subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received the acceptance notice for the marketing application of the drug Patuzumab Injection from the National Medical Products Administration [1] Group 1 - The acceptance of the marketing application is a significant step for the company in advancing its product pipeline [1] - The drug Patuzumab Injection is likely to contribute to the company's revenue growth upon successful commercialization [1]

Core Viewpoint - New Horizon announced that its subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received the acceptance notice from the National Medical Products Administration for the marketing application of Pertuzumab injection, targeting HER2-positive breast cancer [1]. Group 1 - The marketing application for Pertuzumab injection has been accepted, indicating progress in the drug's approval process [1]. - Pertuzumab injection is a recombinant humanized anti-HER2 monoclonal antibody that specifically binds to the extracellular dimerization domain II of HER2, blocking the dimerization of HER2 with itself or other HER family members [1]. - The mechanism of action involves blocking the cell cycle and inducing apoptosis, which is crucial for treating HER2-positive breast cancer [1].

Group 1 - Longjian Co., Ltd. won a bid for a highway maintenance project in Heilongjiang with a contract value of 483 million yuan, accounting for 2.64% of the company's expected revenue for 2024 [1] - Transsion Holdings plans to issue H-shares and list on the main board of the Hong Kong Stock Exchange [1] - Good Home's controlling shareholder intends to reduce its stake by up to 2.7%, equivalent to no more than 39.4468 million shares [1][2] Group 2 - Xinhua Insurance reported a cumulative premium income of 181.973 billion yuan from January to October, representing a year-on-year growth of 17% [2][4] - Zhejiang Jiaokao is part of a consortium that plans to bid for a new urbanization project with an estimated total investment of 11.103 billion yuan [4] Group 3 - Changchun High-tech received approval for clinical trials of a vaccine for adolescents and adults [6] - XinNuoWei's application for the listing of Pertuzumab injection has been accepted, targeting HER2-positive breast cancer [8] - Dash Smart won a bid for an intelligent project at the new Huanggang Port inspection building, valued at 55.056 million yuan, which is 1.74% of its expected revenue for 2024 [8] Group 4 - Electronic City is involved in a lawsuit for debt recovery, with the amount in dispute estimated at 777 million yuan [9] - Haibo Technology signed a strategic cooperation agreement with CATL for a cumulative procurement of no less than 200 GWh of electricity from 2026 to 2028 [10] Group 5 - Renfu Pharmaceutical's HW231019 tablets have entered the second phase of clinical trials for postoperative pain relief [11] - Tonghua Dongbao received a drug registration certificate for Aspart Insulin injection from the Dominican Republic [11] Group 6 - Shaanxi Construction reported winning major projects worth a total of 1.016 billion yuan in October [12] - Fuzhou Environmental Protection plans to change its stock name to "Fuzhou Technology" [12] Group 7 - Panlong Pharmaceutical's gel patch for knee osteoarthritis has received approval for clinical trials [15] - Zhongyida's application for a specific stock issuance has been terminated by the Shanghai Stock Exchange [16] Group 8 - Zhizhong Home's controlling shareholder reduced its holdings of convertible bonds by 905,000 units, accounting for 13.51% of the total issued [19] - Haibo Co., Ltd. plans to establish a subsidiary with an investment of 1 billion yuan for high-end component projects [21] Group 9 - Caina Co. plans to use 57 million yuan of idle funds to purchase structured deposits [23] - Zhendong Pharmaceutical's new drug for acute ischemic stroke has entered the IIa phase of clinical trials [25] Group 10 - Weiman Sealing's overseas subsidiary plans to lease a factory in Saudi Arabia for 5 years at a total rent of approximately 54.039 million yuan [26] - Yiling Pharmaceutical's application for Memantine Hydrochloride has been approved for market entry [28] Group 11 - Dongfang Zhizao plans to acquire 70% of Saifu Machinery for 27.4887 million yuan [30] - JianKai Technology's actual controller intends to transfer 3% of the company's shares through inquiry [31] Group 12 - Rejing Bio plans to repurchase shares worth between 100 million and 200 million yuan [32] - Bangji Technology has decided to terminate a major asset restructuring project due to failure to reach an agreement [34] Group 13 - Huadong Pharmaceutical's application for the marketing license of a new drug has been accepted [36] - Zhonggu Logistics' shareholder plans to reduce its stake by up to 3% [38] Group 14 - Bohui Innovation's subsidiary received approval for a clinical trial of a vaccine for invasive infections [40] - Shannon Chip's shareholder pledged 0.27% of the company's shares for financing [42] Group 15 - Shanghai Petrochemical appointed a new general manager [44] - Jiaojian Co. plans to reduce the holdings of some directors and executives by up to 0.35% [46] Group 16 - Weiting Electric plans to raise no more than 300 million yuan through a private placement [47] - Zhongjin Irradiation plans to invest approximately 200 million yuan in an electronic accelerator manufacturing project [49] Group 17 - Tongxing Technology signed a framework agreement to invest 3.2 billion yuan in a sodium battery project [50] - Hongri Da plans to establish a subsidiary focused on semiconductor packaging [51] Group 18 - Shanghai Kaibao's new drug for acute ischemic stroke has received approval for clinical trials [53] - Yitong Century announced a change in its control structure, becoming a company without a controlling shareholder [55]

Core Viewpoint - The announcement indicates that the company's subsidiary, Giant Biopharmaceutical Co., Ltd., has received the acceptance notice from the National Medical Products Administration for the marketing application of Pertuzumab injection, marking a significant step in the company's oncology product pipeline [1] Group 1: Product Details - Pertuzumab injection is a recombinant humanized anti-HER2 monoclonal antibody administered every three weeks [1] - The product works by specifically binding to the extracellular dimerization domain II of HER2, blocking the dimerization of HER2 with itself or other HER family members, thereby inhibiting the cell cycle and inducing apoptosis [1] - The application is based on a Phase III equivalence clinical trial involving patients with early or locally advanced HER2-positive breast cancer, demonstrating that the product is equivalent to the reference drug for neoadjuvant treatment [1] Group 2: Clinical Trial Results - Clinical trial results indicate that the safety and tolerability of the product are good and similar to the reference drug [1]